LENZ Therapeutics is progressing rapidly with its LNZ100 for presbyopia, aiming for a 2025 U.S. launch in a market valued at ...

Not only are biotech stocks subject to the boom-or-bust nature of their therapeutics, but they also operate in a cyclical ...

Sapirstein had only held the title for 32 days, assuming the executive chairman role after the company’s latest CEO resigned ...

Sangamo, which has been having cash problems, will receive $18 million upfront in licensing fees for its AAV capsid that in ...

Apollomics has tagged out of its partnership with TYG Oncology, terminating an immuno-oncology pact as part of a push to cut ...

Gene therapy and gene editing are on the cutting edge of modern biotechnology. Gene therapies are used to correct genetic abnormalities by introducing genetic material at a cellular level and ...

The group had a bad week after turmoil at the FDA, continuing a long period of underperformance following the pandemic.

Learn more about whether Alvotech or Legend Biotech Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Sangamo Therapeutics has stacked up $18 million cash from Eli Lilly in a licensing deal that will let the pharma use the ...

I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. I-Mab has established operations in the U.S.

Broker Canaccord Genuity says this ASX share potentially 'has no value from here'. Here's what is happening with this ...

BioPharma Credit (LSE: BPCR) is one of the more esoteric investment trusts listed in London. Biotech is a specialist sector ...